Pharmafile Logo

dry eye

- PMLiVE

Challenging perceptions

Alvaro Herreros on the ADHD landscape

- PMLiVE

Baxalta agrees to $32bn Shire takeover

Deal will  create one of the industry's top rare disease firms

Shire Basingstoke

Shire deal with Baxalta predicted this week

Takeover talks reported to be at an advanced stage

Shire Basingstoke

FDA grants fast track designation to Shire’s Cinryze

Kidney transplant treatment in line for regulatory assistance

- PMLiVE

FDA deals a big blow to Shire’s late-stage pipeline

Additional data required before firm can apply for re-approval

- PMLiVE

Shire picks winner for Gaucher film contest

Argentinianfilm My Daughter takes home the competition's top prize

Shire Basingstoke

Shire wins EU approval for prolonged-release ADHD drug

First treatment in its class to be licensed for ADHD in Europe

- PMLiVE

Shire adds Sara Mathew to board of directors

Comes as firm aims to become global biotechnology leader

Shire Basingstoke

Baxalta spells out opposition to Shire

Firm has rejected unsolicited $30bn bid from the Irish biopharma

- PMLiVE

Shire makes shock $30bn bid for Baxalta

Irish firm seeking to buy the newly spun-out biotech that used to be part of Baxter

Shire Basingstoke

Shire buys into eyecare specialist

Will complement its investigational dry eye drug lifitegrast

Shire Basingstoke

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links